Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veldoreotide - Strongbridge Biopharma

Drug Profile

Veldoreotide - Strongbridge Biopharma

Alternative Names: COR-005; DG-3173; PTR-3173; Somatoprim; Veldoreotide extended release; Veldotide

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peptor
  • Developer Strongbridge Biopharma
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Adrenal cortical hyperfunction; Diabetic retinopathy; Neuroendocrine tumours

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for preclinical development in Acromegaly in USA (Controlled release)
  • 05 Oct 2021 Strongbridge Biopharma and Xeris Pharmaceuticals has been acquired by Xeris Biopharma Holdings
  • 23 May 2021 Strongbridge Biopharma has six pending patent applications for veldoreotide in China, Japan, Canada and various countries in Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top